Prevention & lipidsCohort study
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
- Population-based cohort study
Authors' conclusion
Among patients with ASCVD, hypertriglyceridaemia is common, and is associated with higher ASCVD risk across a range of TG.
Study context
- Population
- Adults with prevalent atherosclerotic cardiovascular disease (ASCVD) and lipid panels, Ontario populationwith ASCVD
- Participants
- 196,717 adults
- Exposure
- Higher vs lower triglyceride levels
- Outcome
- ASCVD events:
- First MI
- Unstable angina
- Stroke or TIA
- Coronary revascularization
- CV death
- Follow-up
- Mean (SD) 2.9 (0.5) years
Main finding
As reported in the abstract
ASCVD events by TG
Composite ASCVD events
24 097
Observational data: associations, not effects.
Further findings
Potential icosapent ethyl eligibility (triglyceride (TG) 135-499 mg/dL and low-density lipoprotein cholesterol (LDLc) 41-100 mg/dL)
- Hypertriglyceridaemia with controlled LDLc
- 25% (49 886)
- Demographically similar to REDUCE-IT with comparable event rates
Original publication
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. Eur Heart J. Published 16 November 2019. doi:10.1093/eurheartj/ehz767
Summarised from the published abstract; every number is checked against it